国际膀胱癌工作组低级别膀胱肿瘤风险适应性管理推荐
国际膀胱癌工作组基于截至2019年3月的文献与专家共识,针对低级别非肌层浸润性膀胱癌提出诊断、治疗与监测推荐,强调低级别Ta肿瘤进展风险极低,应以减少患者负担为目标,诊室膀胱镜电灼或主动监测可作为稳定复发的管理选项,并建议临床研究以复发率而非进展事件为主要终点。
要点
- 低级别Ta膀胱癌进展风险极低,管理目标为减少患者负担。
- 稳定低级别复发可用诊室膀胱镜电灼或主动监测方案处理。
- 不建议常规尿细胞学检查,监测膀胱镜可于5年后停止。
核心结论
- 低级别非肌层浸润性膀胱癌进展风险极低,应以减少患者负担为目标进行管理。
研究设计与样本
- 国际膀胱癌工作组回顾截至2019年3月发表的试验、指南、荟萃分析与综述,基于专家共识形成推荐。
主要发现
- 低级别Ta膀胱癌对患者进展与疾病特异性生存的风险极小。
- 初次诊断低级别Ta肿瘤后,后续稳定的低级别表现复发可用诊室膀胱镜电灼或主动监测方案保守管理。
关键数值与推荐
- 除单次围手术期化疗灌注外,膀胱内治疗应审慎使用,且仅在赋予适当风险评分后使用。
- 除初始风险分层或未治疗的主动监测患者外,不建议常规使用尿细胞学检查。
- 监测膀胱镜可于5年后停止。
- 该组患者的临床研究应关注复发率与复发时间,而非进展事件。
临床怎么用
- 对低级别Ta膀胱癌稳定复发可选择诊室膀胱镜电灼或主动监测以减少有创干预。
- 膀胱内治疗除单次围手术期化疗外应审慎,并先进行风险评分。
- 避免常规尿细胞学检查,监测膀胱镜可于5年后停止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To provide a contemporary update and recommendations for the diagnosis and management of low-grade non-muscle-invasive bladder cancer (BCa) based on current literature and expert consensus of the International Bladder Cancer Group. METHODS: We reviewed published trials, guidelines, meta-analyses and reviews (up to March 2019) and provide recommendations on baseline evaluations, treatment, endpoints, study design and surveillance protocols. RESULTS: Low-grade Ta BCa poses minimal risk to patients in terms of progression and disease-specific survival. Thus, to minimize patient morbidity, this entity should be managed appropriately. After initial diagnosis of low-grade Ta tumour, subsequent stable, low-grade-appearing recurrences can be managed conservatively with office cystoscopy and fulguration or even followed using an active surveillance protocol. Intravesical therapy other than single-dose peri-operative chemotherapy instillation should be used judiciously, and only after assigning appropriate risk points. Routine use of urinary cytology - other than at initial risk stratification, or for patients on active surveillance without therapy - is not recommended; and surveillance cystoscopy may be discontinued after 5 years. Clinical studies in this group of patients should focus on recurrence rates, and time to recurrence, rather than progression events. CONCLUSIONS: The International Bladder Cancer Group has developed formal recommendations regarding the diagnosis, treatment and surveillance of low-grade non-muscle-invasive BCa to minimize morbidity and encourage uniformity among studies in this disease.
引用
- Matulay JT, Soloway M, Witjes JA, et al. Risk-adapted management of low-grade bladder tumours: recommendations from the International Bladder Cancer Group (IBCG). BJU Int. 2020. PMID: 31950596. doi:10.1111/bju.14995
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。